DLC-1 Antibodies

Santa Cruz Biotechnology offers a broad range of DLC-1 monoclonal antibodies for research focused on understanding DLC-1 protein function. The monoclonal antibodies are suitable for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). DLC-1, or Deleted in Liver Cancer 1, functions as a tumor suppressor protein with significant influence on cell growth and migration patterns. Research has shown that changes in DLC-1 expression correlate with various types of cancer development, particularly in liver cancer. Investigating DLC-1 activity continues to reveal new insights about cancer formation and progression. Understanding DLC-1's molecular mechanisms helps identify potential therapeutic approaches for cancer treatment. Current studies indicate that DLC-1 influences multiple cellular pathways involved in tumor suppression. Ongoing research aims to fully map DLC-1's role in maintaining cellular health and preventing malignant transformation. Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance scientific understanding of DLC-1's role in cancer biology and therapeutic development.